Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: EARNINGS, HEALTH, TRADE SHOWS/SEMINARS/WEBINARS

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results


New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

"Across the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks," said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. "Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

"ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women," said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. "To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year's IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic."

ADG20 COVID-19 Program Highlights

Recent Business Highlights

Second Quarter 2021 Financial Results

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading "Risk Factors" in Adagio's prospectus filed with the Securities and Exchange Commission ("SEC") on August 6, 2021 and in Adagio's future reports to be filed with the SEC, including Adagio's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
[email protected]

Investor Contact:
Monique Allaire, THRUST Strategic Communications
[email protected]


ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

  June 30,
2021
  December 31,
2020
 
Assets      
Current assets:      
Cash and cash equivalents(1) $392,509  $114,988 
Prepaid expenses and other current assets  3,550   2,394 
Total current assets  396,059   117,382 
Deferred offering costs  1,933   ? 
Total assets $397,992  $117,382 
Liabilities, Convertible Preferred Stock and Stockholders' Deficit      
Current liabilities:      
Accounts payable $10,716  $8,153 
Accrued expenses  27,181   4,919 
Total current liabilities  37,897   13,072 
Early-exercise liability  8   11 
Total liabilities  37,905   13,083 
Commitments and contingencies      
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively  504,711   169,548 
Stockholders' deficit:      
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020  1   1 
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively  ?   (85)
Additional paid-in capital  4,067   154 
Accumulated deficit  (148,692)  (65,319)
Total stockholders' deficit  (144,624)  (65,249)
Total liabilities, convertible preferred stock and stockholders' deficit $397,992  $117,382 

(1)     Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

  Three Months
Ended
June 30,
  Six Months
Ended
June 30,
  Period from
June 3, 2020
(Inception) to
June 30,
 
  2021  2021  2020 (3) 
Operating expenses:         
Research and development(1) $35,067  $69,204  $48 
Acquired in-process research and development(2)  2,500   3,500   ? 
Selling, general and administrative  7,124   10,695   50 
Total operating expenses  44,691   83,399   98 
Loss from operations  (44,691)  (83,399)  (98)
Other income (expense):         
Interest income  23   32   ? 
Other expense  (5)  (6)  ? 
Total other income (expense), net  18   26   ? 
Net loss and comprehensive loss $(44,673) $(83,373) $(98)
Net loss per share attributable to common stockholders, basic and
diluted
 $(0.18) $(0.66) $? 
Weighted-average common shares outstanding, basic and diluted  249,769   125,574   21,250,000 

?(1)   Includes related-party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2)   Includes related-party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3)   The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.?



These press releases may also interest you

at 08:45
Change Your Brain Foundation announced today it has been named a "2024 Top-Rated Nonprofit" by GreatNonprofits, the leading website for community recommendations of charities and nonprofits. Change Your Brain Foundation, established in 2008 by...

at 08:44
Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features...

at 08:42
It's no secret that if a person is healthy, they can do more than just survive. A healthy individual can have more life experiences, engage in more activities, and enjoy a more fulfilling quality of life. This larger goal of a healthy life well lived...

at 08:41
Wound healing can be a long and complicated process. Along with the healing itself, patients must consider factors such as a clean environment and consistent care. Quality of life can also be impacted by something as simple as unpleasant smells...

at 08:41
In a transformative approach to combating human trafficking in the United States, Safe House Project is revolutionizing the fight against this pervasive crime. By equipping hundreds of thousands of individuals across the nation with the tools to...

at 08:40
The "Global Cell Counting Market: Analysis By Product, By Application, By End-User, By Region Size, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The global cell counting market was valued at US$9.98...



News published on and distributed by: